Commenting on the Indian Supreme Courts ruling on Glivec, Stephen Whitehead, Chief Executive of the ABPI said: "We are very disappointed that the Indian Supreme Court has chosen not to grant a patent claim for Glivec despite it being recognised in 40 other countries including China."
"This decision will not improve access to medicines. In fact in the long term it could actually have the opposite effect, as patent protection is a factor companies consider when deciding whether to launch a new medicine in a particular country. This move may also discourage companies from investing in the discovery of new life-changing and life-saving treatments in the Indian market.”
“There are more constructive approaches to ensuring patients in less well developed countries can access medicines, including differential pricing, which is more effective and sustainable. This approach has already had much success and has led to many companies selling their medicines in a way that allows them to be accessed by the poorest and those least able to afford them. Indeed, many companies, including Novartis, have extensive patient access schemes in place to ensure that vital medicines can be used by those not able to afford them otherwise.”